| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Welfare Analysis of Genetic Testing in Health Insurance Markets with Adverse Selection and Prevention |
0 |
0 |
1 |
36 |
0 |
2 |
6 |
32 |
| A Welfare Analysis of Genetic Testing in Health Insurance Markets with Adverse Selection and Prevention |
0 |
0 |
2 |
26 |
0 |
0 |
2 |
9 |
| A paradoxical risk aversion effect on the consumers’ demand for quality |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
75 |
| Adverse Selection vs Discrimination Risk with Genetic Testing. An Experimental Approach |
0 |
0 |
0 |
30 |
0 |
0 |
2 |
79 |
| Adverse Selection vs Discrimination Risk with Genetic Testing. An Experimental Approach |
0 |
0 |
0 |
50 |
0 |
0 |
0 |
127 |
| Análisis económico de la normativa de libre competencia en Colombia |
0 |
0 |
1 |
19 |
0 |
0 |
2 |
87 |
| Characterization of the relevant market in the media industry: some new evidence! |
0 |
0 |
1 |
71 |
0 |
0 |
5 |
73 |
| Competencia en el sector de la salud: énfasis en el caso colombiano |
0 |
1 |
3 |
63 |
3 |
4 |
9 |
195 |
| Competition among health plans: a two-sided market approach |
0 |
0 |
1 |
292 |
0 |
2 |
13 |
780 |
| Competition between Managed Care Organizations and Indemnity Plans in Health Insurance Markets |
0 |
0 |
1 |
101 |
1 |
4 |
9 |
110 |
| Competition in Health Care Markets and Vertical Restraints |
0 |
0 |
0 |
52 |
0 |
1 |
2 |
222 |
| Competition in Health Care Markets and Vertical Restraints |
0 |
0 |
0 |
173 |
0 |
0 |
1 |
542 |
| Competition in two-sided markets with common network externalities |
0 |
0 |
0 |
166 |
0 |
1 |
1 |
240 |
| Competition in two-sided markets with common network externalities |
0 |
0 |
0 |
167 |
0 |
0 |
0 |
466 |
| Competition in two-sided markets with common network externalities |
0 |
0 |
0 |
212 |
0 |
0 |
0 |
437 |
| Concentration of the Mobile Telecommunications Markets and Countries' Competitiveness |
0 |
1 |
8 |
81 |
0 |
2 |
19 |
236 |
| Controlling Sellers Who Provide Advice: Regulation and Competition |
0 |
0 |
0 |
53 |
0 |
0 |
0 |
145 |
| Controlling Sellers Who Provide Advice: Regulation and Competition* |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
| Controlling Sellers Who Provide Advice: Regulation and Competition* |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14 |
| Coronavirus and Social Distancing: Do Non-Pharmaceutical-Interventions Work (at Least) in the Short Run? |
0 |
0 |
0 |
11 |
2 |
2 |
2 |
25 |
| Coronavirus and Social Distancing: Do Non-Pharmaceutical-Interventions Work (at least) in the Short Run? |
0 |
0 |
0 |
11 |
0 |
0 |
0 |
39 |
| Coronavirus and Social Distancing: Do Non-Pharmaceutical-Interventions Work (at least) in the Short Run? |
0 |
0 |
0 |
15 |
4 |
4 |
7 |
50 |
| Doctors' remuneration schemes and hospital competition in two-sided markets with common network externalities |
0 |
0 |
0 |
74 |
0 |
0 |
1 |
148 |
| Doctors' remuneration schemes and hospital competition in two-sided markets with common network externalities |
0 |
0 |
0 |
60 |
0 |
3 |
6 |
112 |
| Doctors´ remuneration schemes and hospital competition in two-sided markets with common network externalities |
0 |
0 |
0 |
129 |
0 |
0 |
2 |
251 |
| Drugs, Showrooms and Financial Products: Competition and Regulation When Sellers Provide Expert Advice |
0 |
0 |
0 |
15 |
0 |
0 |
0 |
45 |
| Drugs, Showrooms and Financial Products: Competition and Regulation When Sellers Provide Expert Advice |
0 |
0 |
0 |
0 |
1 |
3 |
3 |
17 |
| Drugs, Showrooms and Financial Products: Competition and Regulation when Sellers Provide Expert Advice |
0 |
0 |
3 |
28 |
0 |
0 |
3 |
109 |
| Drugs, Showrooms and Financial Products: Competition and Regulation when Sellers Provide Expert Advice |
0 |
0 |
0 |
26 |
0 |
0 |
0 |
7 |
| Drugs, Showrooms and Financial Products: Competition and Regulation when Sellers Provide Expert Advice |
0 |
0 |
0 |
37 |
0 |
0 |
0 |
60 |
| Drugs, Showrooms and Financial Products: Competition and Regulation when Sellers Provide Expert Advice |
0 |
0 |
0 |
41 |
1 |
1 |
3 |
50 |
| Economic Incentives to Develop and to Use Diagnostic Tests - A Literature Review |
0 |
0 |
0 |
0 |
0 |
3 |
6 |
6 |
| Economic Incentives to Develop and to Use Diagnostic Tests - A Literature Review |
0 |
0 |
4 |
6 |
0 |
3 |
9 |
11 |
| Economic Incentives to Develop and to Use Diagnostic Tests a Literature Review |
0 |
0 |
5 |
19 |
0 |
1 |
9 |
25 |
| El trabajo intermediado por plataformas en Colombia: aspectos conceptuales y propuesta de regulación desde la teoría de contratos y la organización industrial |
0 |
0 |
1 |
9 |
0 |
0 |
3 |
12 |
| Genetic testing with primary prevention and moral hazard |
0 |
0 |
0 |
14 |
0 |
1 |
2 |
79 |
| Genetic testing with primary prevention and moral hazard |
0 |
0 |
0 |
48 |
1 |
3 |
6 |
203 |
| Genetic testing with primary prevention and moral hazard |
0 |
0 |
0 |
28 |
0 |
0 |
2 |
98 |
| Genetic testing with primary prevention and moral hazard |
0 |
0 |
0 |
19 |
2 |
2 |
2 |
84 |
| Genetic testing with primary prevention and moral hazard |
0 |
0 |
0 |
14 |
0 |
0 |
0 |
73 |
| Healt care network formation and policyholders'welfare |
0 |
0 |
1 |
31 |
0 |
0 |
3 |
161 |
| Health Care Insurance Payment Policy when the Physician and Patient May Collude |
0 |
1 |
1 |
10 |
0 |
1 |
1 |
93 |
| Health Care Insurance Payment Policy when the Physician and Patient May Collude |
0 |
0 |
0 |
20 |
0 |
0 |
1 |
63 |
| Health Care Network Formation and Policyholders' Welfare |
0 |
0 |
0 |
48 |
0 |
0 |
1 |
136 |
| Health Care Providers Payments Regulation when Horizontal and Vertical Differentiation Matter |
0 |
0 |
0 |
133 |
0 |
0 |
0 |
425 |
| Health Care Providers Payments Regulation when Horizontal and Vertical Differentiation Matter |
0 |
0 |
0 |
57 |
0 |
0 |
0 |
201 |
| Health Insurance and Diversity of Treatment: A Policy Mix Perspective |
0 |
0 |
0 |
36 |
0 |
0 |
0 |
117 |
| Health care insurance payment policy when the provider and patient May Collude |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
4 |
| Health insurance and diversity of treatment: a policy mix perspective |
0 |
0 |
0 |
28 |
1 |
1 |
3 |
84 |
| How Is the Trade-off between Adverse Selection and Discrimination Risk Affected by Genetic Testing? Theory and Experiment |
0 |
0 |
0 |
35 |
0 |
0 |
0 |
121 |
| How Is the Trade-off between Adverse Selection and Discrimination Risk Affected by Genetic Testing?: Theory and Experiment |
0 |
1 |
1 |
59 |
0 |
2 |
3 |
68 |
| How is the Trade-off between Adverse Selection and Discrimination Risk Affected by Genetic Testing? Theory and Experiment |
0 |
0 |
0 |
63 |
0 |
1 |
3 |
81 |
| Incentivizing Physicians' Diagnostic Effort and Test with Moral Hazard and Adverse Selection |
1 |
5 |
5 |
5 |
6 |
12 |
12 |
12 |
| Incentivizing Physicians' Diagnostic Effort and Test with Moral Hazard and Adverse Selection |
1 |
2 |
4 |
4 |
1 |
7 |
11 |
11 |
| Informality and Optimal Public Policy |
0 |
0 |
1 |
36 |
0 |
0 |
1 |
47 |
| Informality and Optimal Public Policy |
1 |
1 |
1 |
43 |
2 |
2 |
4 |
151 |
| Informality and optimal public policy |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
| Integración vertical en el sector de la salud colombiano |
0 |
0 |
2 |
58 |
0 |
0 |
4 |
160 |
| La economía de los mercados de dos lados: aplicación al análisis de las tarjetas de pago en Colombia |
0 |
0 |
4 |
205 |
0 |
0 |
9 |
852 |
| Nursing Homes' Competition and Distributional Implications when the Market is Two-Sided |
0 |
0 |
0 |
34 |
0 |
0 |
0 |
61 |
| Nursing Homes’ Competition and Distributional Implications when the Market is Two-Sided |
0 |
0 |
1 |
15 |
0 |
0 |
4 |
70 |
| Nursing homes' competition and distributional implications when the market is two-sided |
0 |
0 |
0 |
7 |
0 |
0 |
2 |
15 |
| Physicians' Incentives to Adopt Personalized Medicine: Experimental Evidence |
0 |
0 |
0 |
42 |
2 |
2 |
2 |
39 |
| Physicians’ Incentives to Adopt Personalized Medicine: Experimental Evidence |
0 |
0 |
0 |
9 |
0 |
1 |
2 |
30 |
| Physicians’ incentives to adopt personalised medicine: Experimental evidence |
0 |
0 |
0 |
9 |
0 |
0 |
0 |
15 |
| Physicians’ incentives to adopt personalized medicine: experimental evidence |
0 |
0 |
0 |
45 |
0 |
1 |
2 |
41 |
| Physicians’ incentives to adopt personalized medicine: experimental evidence |
0 |
0 |
0 |
6 |
0 |
1 |
3 |
53 |
| Precios máximos de venta en el mercado de medicamentos colombiano: una evaluación de impacto |
0 |
0 |
1 |
30 |
2 |
2 |
5 |
109 |
| Price cap regulation in the Colombian pharmaceutical market: An impact evaluation |
0 |
0 |
1 |
10 |
0 |
0 |
1 |
30 |
| Price cap regulation in the Colombian pharmaceutical market: An impact evaluation |
0 |
1 |
4 |
13 |
0 |
1 |
6 |
49 |
| Retail Price Regulation and Innovation: Reference Pricing in the Pharmaceutical Industry |
0 |
0 |
1 |
309 |
3 |
3 |
9 |
867 |
| Retail Price Regulation and Innovation: Reference Pricing in the Pharmaceutical Industry |
0 |
0 |
0 |
85 |
2 |
2 |
4 |
303 |
| Seguros de desempleo: revisión de literatura y propuesta para Colombia |
0 |
0 |
1 |
205 |
0 |
0 |
3 |
866 |
| Small-area variation in health care affecting the choice of cesarean delivery: the case of a colombian health insurer |
0 |
0 |
0 |
81 |
0 |
0 |
1 |
409 |
| Supplementary health insurance in the Colombian managed care system: Adverse or advantageous selection? |
0 |
0 |
0 |
33 |
0 |
0 |
0 |
46 |
| Supplementary health insurance in the Colombian managed care system: ¿Adverse or advantageous selection? |
0 |
0 |
0 |
12 |
0 |
1 |
4 |
61 |
| Teoría del control óptimo: ¡Una guía para principiantes! |
1 |
1 |
5 |
1,168 |
1 |
2 |
12 |
3,849 |
| Teorías y algunas experiencias internacionales en el financiamiento de la educación superior: lecciones para Colombia |
0 |
0 |
2 |
184 |
0 |
0 |
8 |
1,192 |
| The Design of Insurance Coverage for Medical Products under Imperfect Competition |
0 |
0 |
0 |
19 |
0 |
0 |
0 |
75 |
| The Design of Insurance Coverage for Medical Products under Imperfect Competition |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
74 |
| The Health Technology Assessment Approach of The Economic Value of Diagnostic Test: A Literature Review |
0 |
0 |
14 |
15 |
0 |
1 |
18 |
19 |
| The Health Technology Assessment Approach of the Economic Value of Diagnostic Tests - A Literature Review |
0 |
1 |
2 |
2 |
0 |
2 |
8 |
8 |
| The Health Technology Assessment Approach of the Economic Value of Diagnostic Tests - A Literature Review |
0 |
0 |
3 |
3 |
0 |
4 |
9 |
9 |
| The design of insurance coverage for medical products under imperfect competition |
0 |
0 |
0 |
9 |
0 |
0 |
0 |
75 |
| The design of insurance coverage for medical products under imperfect competition |
0 |
0 |
0 |
22 |
0 |
0 |
0 |
77 |
| The regulation of health care providers' payments when horizontal and vertical differentiation matter |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
46 |
| Unemployment Insurance in the Presence of an Informal Sector |
0 |
1 |
2 |
84 |
0 |
1 |
4 |
204 |
| Unemployment insurance and informality in developing countries |
0 |
0 |
1 |
76 |
1 |
1 |
2 |
150 |
| Unemployment insurance and informality in developing countries |
0 |
0 |
4 |
113 |
1 |
4 |
16 |
334 |
| Unemployment insurance in the presence of an informal |
0 |
0 |
0 |
43 |
0 |
0 |
2 |
136 |
| Unemployment insurance/severance payments and informality in developing countries |
0 |
0 |
1 |
23 |
0 |
0 |
1 |
112 |
| Voluntary Health Plan Subsidies and Public Expenditure |
0 |
0 |
0 |
16 |
0 |
1 |
1 |
77 |
| Voluntary Health Plan Subsidies and Public Expenditure |
0 |
0 |
0 |
19 |
0 |
1 |
1 |
67 |
| Voluntary Health Plan Subsidies and Public Expenditure |
0 |
0 |
0 |
5 |
1 |
2 |
4 |
54 |
| Welfare Impacts of Genetic Testing in Health Insurance Markets: Will Cross-Subsidies Survive? |
0 |
0 |
0 |
4 |
0 |
0 |
5 |
45 |
| ¿Tiene efectos negativos el TLC sobre los precios de los medicamentos y la salud de los colombianos? |
0 |
0 |
0 |
145 |
0 |
0 |
2 |
1,098 |
| Total Working Papers |
4 |
16 |
94 |
5,976 |
38 |
102 |
336 |
18,936 |
LogEc is hosted by the
Örebro University School of Business.